From: Counteracting learned non-use in chronic stroke patients with reinforcement-induced movement therapy
Within-group analysis | Between-group analysis | |||||||
---|---|---|---|---|---|---|---|---|
Mean (SD) - Median 95 % confidence interval for the mean (lower and upper bound) | p-values | |||||||
End of treatment | Change from | p-values | Follow-up | Change from | p-values | Change from | Change from | |
T1 | baseline to T1 | T2 | baseline to T2 | baseline to T1 | baseline to T2 | |||
UE-FM | ||||||||
EG | 38.33 (17.30) – 39 | 6.00 (6.31) – 4 | .008 | 46.22 (14.96) – 52 | 13.89 (9.88) – 10 | .004 | ||
[25.04–51.63] | [1.15–10.85] | [34.72–57.73] | [6.29–21.48] | |||||
.715 | .037 | |||||||
CG | 43.22 (12.62) – 44 | 6.33 (4.50) – 7 | .008 | 41.78 (12.47) – 40 | 4.89 (4.31) – 5 | .016 | ||
[33.52–52.92] | [2.87–9.79] | [32.19–51.36] | [1.57–8.20] | |||||
CAHAI | ||||||||
EG | 33.56 (15.08) – 36 | 1.00 (1.66) – 0 | .125 | 25.11 (16.04) – 42 | 2.56 (4.64) – 1 | .094 | ||
[21.96–45.15] | [-0.27–2.27] | [22.78 – 47.44] | [-1.01–6.12] | |||||
.553 | .552 | |||||||
CG | 34.22 (14.71) – 43 | 0.89 (2.37) – 0 | .500 | 34.89 (14.34) – 43 | 1.56 (3.64) – 0 | .250 | ||
[22.91–45.53] | [-0.93–2.71] | [23.87–45.91] | [-1.25–4.36] | |||||
BI | ||||||||
EG | 85.56 (10.90) – 88 | 0.22 (0.67) – 0 | 1.000 | 87.78 (8.27) – 90 | 2.44 (5.18) – 0 | .125 | ||
[77.18–93.93] | [-0.29–0.73] | [81.42–94.14] | [-1.53–6.42] | |||||
1.000 | .241 | |||||||
CG | 91 (6.69) – 90 | 0.44 (1.33) – 0 | 1.000 | 91 (6.69) – 90 | 0.44 (1.33) – 0 | 1.000 | ||
[85.86–96.14] | [-0.58–1.47] | [85.86–96.14] | [-0.58–1.47] | |||||
Hamilton | ||||||||
EG | 13.89 (9.61) – 8 | -0.56 (1.13) – 0 | .500 | 13.67 (9.85) – 8 | -0.78 (1.39) – 0 | .250 | ||
[6.50–21.28] | [-1.42–0.31] | [6.10–21.24] | [-1.85–0.29] | |||||
.506 | .776 | |||||||
CG | 10.78 (10.15) – 5 | -1.67 (2.83) – 0 | .250 | 11.67 (11.87) – 5 | -0.78 (3.93) – 0 | .688 | ||
[2.98–18.58] | [-3.84–0.51] | [2.54–20.79] | [-3.80–2.24] |